Total Payments
$404,240
2024 Payments
$60,673
Companies
24
Transactions
585
Medicare Patients
1,310
Medicare Billing
$248,611
Payment Breakdown by Category
Other$355,071 (87.8%)
Travel$23,619 (5.8%)
Food & Beverage$14,555 (3.6%)
Consulting$10,930 (2.7%)
Education$64.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $353,071 | 212 | 87.3% |
| Travel and Lodging | $23,619 | 91 | 5.8% |
| Food and Beverage | $14,555 | 274 | 3.6% |
| Consulting Fee | $10,930 | 5 | 2.7% |
| Honoraria | $2,000 | 1 | 0.5% |
| Education | $64.54 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $137,583 | 80 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $95,884 | 128 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $70,240 | 100 | $0 (2023) |
| Lilly USA, LLC | $62,717 | 140 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $28,465 | 56 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $5,643 | 10 | $0 (2019) |
| AstraZeneca UK Limited | $1,375 | 1 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $541.81 | 27 | $0 (2020) |
| Medtronic, Inc. | $372.26 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $354.32 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $60,673 | 54 | Novo Nordisk Inc ($36,407) |
| 2023 | $105,808 | 123 | Novo Nordisk Inc ($51,867) |
| 2022 | $108,784 | 150 | Novo Nordisk Inc ($46,180) |
| 2021 | $80,593 | 97 | AstraZeneca Pharmaceuticals LP ($38,563) |
| 2020 | $28,317 | 53 | AstraZeneca Pharmaceuticals LP ($18,571) |
| 2019 | $16,375 | 61 | Regeneron Pharmaceuticals, Inc. ($5,643) |
| 2018 | $3,503 | 38 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($2,866) |
| 2017 | $186.24 | 9 | Janssen Pharmaceuticals, Inc ($68.54) |
All Payment Transactions
585 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $33.94 | General |
| Category: Cardiovascular | ||||||
| 11/07/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 10/01/2024 | Biobeat USA Inc. | BB-613 BPM kit (Device) | Food and Beverage | Cash or cash equivalent | $39.22 | General |
| Category: Hypertension Diagnosis | ||||||
| 09/04/2024 | LANTHEUS MEDICAL IMAGING, INC. | DEFINITY (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: CONTRAST AGENT | ||||||
| 08/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: DIABETES | ||||||
| 08/21/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Not Applicable | ||||||
| 08/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $27.12 | General |
| Category: Cardiology | ||||||
| 08/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $584.88 | General |
| Category: DIABETES | ||||||
| 07/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,425.00 | General |
| Category: DIABETES | ||||||
| 06/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 06/25/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $27.03 | General |
| Category: Cardiovascular | ||||||
| 05/20/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 05/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,760.00 | General |
| Category: DIABETES | ||||||
| 05/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $101.47 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/26/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| 04/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $123.27 | General |
| Category: DIABETES | ||||||
| 04/22/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 04/22/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| 04/17/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 04/16/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 04/15/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $69.55 | General |
| 04/10/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,393.75 | General |
| 04/10/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| 04/10/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $1,851.10 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 189 | 361 | $185,860 | $38,474 |
| 2022 | 7 | 345 | 645 | $282,287 | $59,825 |
| 2021 | 6 | 430 | 809 | $349,230 | $83,583 |
| 2020 | 5 | 346 | 637 | $276,660 | $66,730 |
Total Patients
1,310
Total Services
2,452
Medicare Billing
$248,611
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 126 | 280 | $114,560 | $29,017 | 25.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 29 | 46 | $44,020 | $4,845 | 11.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $18,400 | $3,170 | 17.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 12 | $8,880 | $1,442 | 16.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 173 | 445 | $173,315 | $40,596 | 23.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 43 | $33,902 | $6,963 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 29 | $21,460 | $4,200 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 61 | 65 | $24,700 | $3,676 | 14.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 12 | 18 | $18,660 | $2,204 | 11.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 31 | $8,990 | $2,006 | 22.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 13 | 14 | $1,260 | $180.20 | 14.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 267 | 623 | $242,970 | $59,064 | 24.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 62 | 65 | $52,000 | $11,833 | 22.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 30 | 45 | $27,780 | $7,423 | 26.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $10,690 | $2,592 | 24.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 35 | 36 | $13,360 | $2,285 | 17.1% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 23 | 27 | $2,430 | $384.84 | 15.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 209 | 488 | $186,330 | $46,949 | 25.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 69 | 72 | $57,600 | $12,904 | 22.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 31 | $15,810 | $3,759 | 23.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 24 | 24 | $10,320 | $2,189 | 21.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 21 | 22 | $6,600 | $929.61 | 14.1% |
About Dr. Nisha Jhalani, MD
Dr. Nisha Jhalani, MD is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2009. The National Provider Identifier (NPI) number assigned to this provider is 1265674618.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nisha Jhalani, MD has received a total of $404,240 in payments from pharmaceutical and medical device companies, with $60,673 received in 2024. These payments were reported across 585 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($353,071).
As a Medicare-enrolled provider, Jhalani has provided services to 1,310 Medicare beneficiaries, totaling 2,452 services with total Medicare billing of $248,611. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New York, NY
- Active Since 04/01/2009
- Last Updated 05/09/2016
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1265674618
Products in Payments
- JARDIANCE (Drug) $158,009
- FARXIGA (Drug) $71,162
- Ozempic (Drug) $59,394
- LifeVest (Device) $28,465
- Rybelsus (Drug) $15,267
- PRALUENT (Biological) $5,643
- XARELTO (Drug) $541.81
- ONYX FRONTIER (Device) $372.26
- Repatha (Biological) $276.04
- LEQVIO (Drug) $241.29
- BRILINTA (Drug) $226.12
- ZIO Patch (Device) $174.93
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (Device) $128.07
- (6346) Intrasight Mobile (Device) $115.22
- ENTRESTO (Drug) $113.03
- Coronary Orbital Atherectomy System (Device) $111.11
- ELIQUIS (Drug) $95.50
- MOUNJARO (Drug) $53.17
- BB-613 BPM kit (Device) $39.22
- PRADAXA (Drug) $26.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Deepak Bhatt, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M